Palo Alto Investors LP increased its position in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 18.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,356,514 shares of the biotechnology company’s stock after acquiring an additional 210,095 shares during the period. Aimmune Therapeutics comprises approximately 1.8% of Palo Alto Investors LP’s holdings, making the stock its 17th largest position. Palo Alto Investors LP owned approximately 2.34% of Aimmune Therapeutics worth $43,178,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Raymond James & Associates raised its holdings in Aimmune Therapeutics by 7.2% in the 4th quarter. Raymond James & Associates now owns 24,737 shares of the biotechnology company’s stock worth $936,000 after acquiring an additional 1,669 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Aimmune Therapeutics by 3.1% in the 4th quarter. Wells Fargo & Company MN now owns 63,158 shares of the biotechnology company’s stock worth $2,388,000 after acquiring an additional 1,892 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Aimmune Therapeutics by 24.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 14,637 shares of the biotechnology company’s stock worth $466,000 after acquiring an additional 2,854 shares during the last quarter. Swiss National Bank raised its holdings in Aimmune Therapeutics by 9.7% in the 4th quarter. Swiss National Bank now owns 40,574 shares of the biotechnology company’s stock worth $1,535,000 after acquiring an additional 3,600 shares during the last quarter. Finally, First Republic Investment Management Inc. purchased a new position in Aimmune Therapeutics in the 4th quarter worth approximately $202,000. Institutional investors own 79.49% of the company’s stock.

In other news, insider Stephen George Dilly sold 61,197 shares of the business’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $32.62, for a total transaction of $1,996,246.14. Following the completion of the sale, the insider now owns 376,505 shares of the company’s stock, valued at approximately $12,281,593.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Douglas T. Sheehy sold 3,296 shares of the business’s stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $33.00, for a total transaction of $108,768.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 364,493 shares of company stock valued at $11,580,119. Company insiders own 14.70% of the company’s stock.

Shares of AIMT opened at $30.19 on Thursday. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -11.57 and a beta of -0.34. Aimmune Therapeutics Inc has a 1-year low of $16.25 and a 1-year high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). During the same quarter last year, the firm posted ($0.52) EPS. equities research analysts predict that Aimmune Therapeutics Inc will post -3.14 earnings per share for the current year.

A number of equities analysts recently weighed in on AIMT shares. Deutsche Bank set a $30.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 20th. Piper Jaffray Companies set a $62.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, April 5th. Roth Capital boosted their price objective on shares of Aimmune Therapeutics from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Wedbush restated a “buy” rating on shares of Aimmune Therapeutics in a report on Friday, February 23rd. Finally, ValuEngine upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $53.67.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.